Form 8-K - Current report:
SEC Accession No. 0000950170-23-067777
Filing Date
2023-12-04
Accepted
2023-12-04 16:28:24
Documents
12
Period of Report
2023-12-01
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K kzr-20231201.htm   iXBRL 8-K 36917
  Complete submission text file 0000950170-23-067777.txt   153910

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kzr-20231201_lab.xml EX-101.LAB 13342
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kzr-20231201.xsd EX-101.SCH 2493
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kzr-20231201_pre.xml EX-101.PRE 9857
6 EXTRACTED XBRL INSTANCE DOCUMENT kzr-20231201_htm.xml XML 4713
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

EIN.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38542 | Film No.: 231463612
SIC: 2834 Pharmaceutical Preparations